{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:01:34Z","timestamp":1793714494241,"version":"4.6.1"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2304605, 2021YFC2500805"],"award-info":[{"award-number":["2022YFC2304605, 2021YFC2500805"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272195"],"award-info":[{"award-number":["82272195"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Sepsis is a clinical syndrome resulting from the interaction between coagulation, inflammation, immunity and other systems. Coagulation activation is an initial factor for sepsis to develop into multiple organ dysfunction. Therefore, anticoagulant therapy may be beneficial for sepsis patients. Heparin possesses a variety of biological activities, so it has a broad prospect in sepsis. Previous studies suggested that patients with sepsis-induced disseminated intravascular coagulation and high disease severity might be suitable for anticoagulant therapy. With the development of artificial intelligence (AI), recent studies have shown that patients with severe coagulation activation represent the targeted patients for anticoagulant therapy in sepsis. However, it remains necessary to accurately define the relevant biomarkers indicative of this phenotype and validate their clinical utility by large randomized controlled trials (RCTs). Analyses of data from early small RCTs, subgroup analyses of large RCTs and meta-analyses have collectively suggested that anticoagulant therapy, particularly the use of heparin, may be an effective approach for managing sepsis patients. Concurrently, debate persists regarding the optimal selection of anticoagulants, proper timing, usage and dosage of administration that should be employed to assess treatment efficacy. The primary mechanisms of heparin are acting on heparan sulfate, histones, high mobility group box 1 and heparin-binding protein, which interfere with the regulation of inflammation, vascular permeability, coagulation, endothelial function and other biological activities. However, the underlying pathophysiological processes mediating the potential therapeutic effects of heparin in the context of sepsis remain incompletely understood and warrant additional rigorous investigation to establish the mechanism more conclusively.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1495260","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:10:55Z","timestamp":1733443855000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Heparin in sepsis: current clinical findings and possible mechanisms"],"prefix":"10.3389","volume":"15","author":[{"given":"Sihan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181c9e31d","article-title":"Microvascular thrombosis and multiple organ dysfunction syndrome","volume":"38","author":"Gando","year":"2010","journal-title":"Crit Care Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-010-1893-6","article-title":"The endothelium: physiological functions and role in microcirculatory failure during severe sepsis","volume":"36","author":"Ait-Oufella","year":"2010","journal-title":"Intensive Care Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201910-1911TR","article-title":"Endothelial responses in sepsis","volume":"202","author":"Joffre","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2021.1988928","article-title":"Endothelial dysfunction: a therapeutic target in bacterial sepsis","volume":"25","author":"Vincent","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15852","article-title":"Intracellular communication and immunothrombosis in sepsis","volume":"20","author":"Iba","year":"2022","journal-title":"J Thromb Hemost"},{"key":"B7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0034-1398376","article-title":"Coagulation in patients with severe sepsis","volume":"41","author":"Levi","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13911","article-title":"Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis","volume":"16","author":"Iba","year":"2018","journal-title":"J Thromb Haemost"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-01-0053","article-title":"The coagulation system and its function in early immune defense","volume":"112","author":"van der Poll","year":"2014","journal-title":"Thromb Haemost"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2016.10.010","article-title":"Blood coagulation in immunothrombosis-At the frontline of intravascular immunity","volume":"28","author":"Gaertner","year":"2016","journal-title":"Semin Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-015-4012-x","article-title":"Understanding platelet dysfunction in sepsis","volume":"42","author":"Pigozzi","year":"2016","journal-title":"Intensive Care Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12107","article-title":"Integrating platelet and coagulation activation in fibrin clot formation","volume":"2","author":"Swieringa","year":"2018","journal-title":"Res Pract Thromb Hemost"},{"key":"B13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.11613\/issn.1846-7482","article-title":"Inflammation and hemostasis","volume":"22","author":"Margetic","year":"2012","journal-title":"Biochem Med (Zagreb)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13054-015-0735-x","article-title":"Local hemostasis, immunothrombosis, and systemic disseminated intravascular coagulation in trauma and traumatic shock","volume":"19","author":"Gando","year":"2015","journal-title":"Crit Care"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-023-06980-6","article-title":"How to manage coagulopathies in critically ill patients","volume":"49","author":"Helms","year":"2023","journal-title":"Intensive Care Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/science.1092385","article-title":"Neutrophil extracellular traps kill bacteria","volume":"303","author":"Brinkmann","year":"2004","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12916-015-0327-2","article-title":"Causes and consequences of coagulation activation in sepsis: an evolutionary medicine perspective","volume":"13","author":"Fiusa","year":"2015","journal-title":"BMC Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.10.013","article-title":"Sepsis, thrombosis and organ dysfunction","volume":"129","author":"Semeraro","year":"2012","journal-title":"Thromb Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-024-07507-3","article-title":"Sepsis-induced coagulopathy: a matter of timeline","volume":"50","author":"Meziani","year":"2024","journal-title":"Intensive Care Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-008-0646-8","article-title":"Autopsy report of\u00a0four\u00a0cases who died from Streptococcus suis infection, with a review of the literature","volume":"28","author":"Yang","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00155.2005","article-title":"Blockade\u00a0of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure","volume":"290","author":"Welty-Wolf","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.5791","article-title":"Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis","volume":"321","author":"Seymour","year":"2019","journal-title":"Jama"},{"key":"B23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13054-021-03541-5","article-title":"Coagulation phenotypes in sepsis and effects of recombinant human thrombomodulin: an analysis of three multicenter observational studies","volume":"25","author":"Kudo","year":"2021","journal-title":"Crit Care"},{"key":"B24","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Efficacy and safety of recombinant human activated protein C for severe sepsis","volume":"344","author":"Bernard","year":"2001","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016","volume":"43","author":"Rhodes","year":"2017","journal-title":"Intensive Care Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40560-021-00555-7","article-title":"The Japanese clinical practice guidelines for management of sepsis and septic shock 2020 (J-SSCG 2020)","volume":"9","author":"Egi","year":"2021","journal-title":"J Intensive Care"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.2.238","article-title":"Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial","volume":"290","author":"Abraham","year":"2003","journal-title":"Jama"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202290","article-title":"Drotrecogin alfa (activated) in adults with septic shock","volume":"366","author":"Ranieri","year":"2012","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"R297","DOI":"10.1186\/cc13163","article-title":"A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis","volume":"17","author":"Gando","year":"2013","journal-title":"Crit Care"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31828e9b03","article-title":"A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation","volume":"41","author":"Vincent","year":"2013","journal-title":"Crit Care Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.15.1869","article-title":"Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial","volume":"286","author":"Warren","year":"2001","journal-title":"Jama"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60411-5","article-title":"Drotrecogin alfa (activated) in children with severe sepsis: a multicenter phase III randomized controlled trial","volume":"369","author":"Nadel","year":"2007","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e318258ff30","article-title":"Severe sepsis, coagulation, and fibrinolysis: dead end or one way","volume":"40","author":"Fourrier","year":"2012","journal-title":"Crit Care Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13054-016-1415-1","article-title":"Benefit profile of anticoagulant therapy in sepsis: a nationwide multicenter registry in Japan","volume":"20","author":"Yamakawa","year":"2016","journal-title":"Crit Care"},{"key":"B36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13054-019-2372-2","article-title":"Heterogeneity in sepsis: new biological evidence with clinical applications","volume":"23","author":"Leligdowicz","year":"2019","journal-title":"Crit Care"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1055\/s-0040-1719037","article-title":"Artificial intelligence in the intensive care unit","volume":"42","author":"Greco","year":"2021","journal-title":"Semin Respir Crit Care Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13054-022-04020-1","article-title":"Web-based application for predicting the potential target phenotype for recombinant human thrombomodulin therapy in patients with sepsis: analysis of three multicenter registries","volume":"26","author":"Goto","year":"2022","journal-title":"Crit Care"},{"key":"B39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.0960-135X.2005.01452.x","article-title":"From heparins to factor Xa inhibitors and beyond","author":"Alban","year":"2005","journal-title":"Eur J Clin Invest"},{"key":"B40","article-title":"Therapeutic effects of early administration of low-dose heparin in patients with severe sepsis","volume":"44","author":"Zhang","year":"2006","journal-title":"Chin J Surg"},{"key":"B41","article-title":"Evaluation of clinical effects on low-dose heparin therapy for sepsis","volume":"48","author":"Zhao","year":"2009","journal-title":"Chin J Intern Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31818b8c6b","article-title":"Early intravenous unfractionated heparin and mortality in septic shock","volume":"36","author":"Zarychanski","year":"2008","journal-title":"Crit Care Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31819c06bc","article-title":"Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study)","volume":"37","author":"Jaimes","year":"2009","journal-title":"Crit Care Med"},{"key":"B44","article-title":"Heparin for treatment of sepsis: a systemic review","volume":"26","author":"Liu","year":"2014","journal-title":"Chin Crit Care Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1186\/s13054-014-0563-4","article-title":"Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis","volume":"18","author":"Wang","year":"2014","journal-title":"Crit Care"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000000763","article-title":"The efficacy and safety of heparin in patients with sepsis: a systematic review and meta-analysis","volume":"43","author":"Zarychanski","year":"2015","journal-title":"Crit Care Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.2017.179.issue-3","article-title":"The role of heparin in sepsis: much more than just an anticoagulant","volume":"179","author":"Li","year":"2017","journal-title":"Br J Hematol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12871-021-01545-w","article-title":"Unfractionated heparin improves the clinical efficacy in adult sepsis patients: a systematic review and meta-analysis","volume":"22","author":"Fu","year":"2022","journal-title":"BMC Anesthesiol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.773339","article-title":"Favorable outcomes of anticoagulation with unfractioned heparin in sepsis-induced coagulopathy: A retrospective analysis of MIMIC-III database","volume":"8","author":"Peng","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"tkac029","DOI":"10.1093\/burnst\/tkac029","article-title":"Early prophylactic anticoagulation with heparin alleviates mortality in critically ill patients with sepsis: a retrospective analysis from the MIMIC-IV database","volume":"10","author":"Zou","year":"2022","journal-title":"Burns Trauma"},{"key":"B51","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.cjtee.2023.04.006","article-title":"Why anticoagulant studies on sepsis fail frequently \u2014 start with SCARLET","volume":"26","author":"Guo","year":"2023","journal-title":"Chin J Traumatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12967-022-03469-6","article-title":"Clinical applications of machine learning in the survival prediction and classification of sepsis: coagulation and heparin usage matter","volume":"20","author":"Guo","year":"2022","journal-title":"J Transl Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1213\/ANE.0000000000006888","article-title":"Sepsis-induced coagulopathy: A comprehensive narrative review of pathophysiology, clinical presentation, diagnosis, and management strategies","volume":"138","author":"Williams","year":"2024","journal-title":"Anesth Analg"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-2222","article-title":"Identification of soluble thrombomodulin and tissue plasminogen activator-inhibitor complex as biomarkers for prognosis and early evaluation of septic shock and sepsis-induced disseminated intravascular coagulation","volume":"10","author":"Zhang","year":"2021","journal-title":"Ann Palliat Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2021.0008","article-title":"Damage-associated molecular patterns as double-edged swords in sepsis","volume":"35","author":"Zhou","year":"2021","journal-title":"Antioxid Redox Signal"},{"key":"B56","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/ph16020271","article-title":"Heparin, heparan sulphate and sepsis: potential new options for treatment","volume":"16","author":"Hogwood","year":"2023","journal-title":"Pharm (Basel)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00532.2014","article-title":"A microscopic view on the renal endothelial glycocalyx","volume":"308","author":"Dane","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14371","article-title":"Derangement of the endothelial glycocalyx in sepsis","volume":"17","author":"Iba","year":"2019","journal-title":"J Thromb Haemost"},{"key":"B59","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13054-018-2292-6","article-title":"The glycocalyx: a novel diagnostic and therapeutic target in sepsis","volume":"23","author":"Uchimido","year":"2019","journal-title":"Crit Care"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2019.8285","article-title":"Both UFH and NAH alleviate shedding of endothelial glycocalyx and coagulopathy in LPS-induced sepsis","volume":"19","author":"Huang","year":"2020","journal-title":"Exp Ther Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12950-020-0238-7","article-title":"Different signaling pathways involved in the anti-inflammatory effects of unfractionated heparin on lipopolysaccharide-stimulated human endothelial cells","volume":"17","author":"Li","year":"2020","journal-title":"J Inflammation (Lond)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"9985397","DOI":"10.1155\/2021\/9985397","article-title":"Unfractionated heparin improves the intestinal microcirculation in a canine septic shock model","volume":"2021","author":"Zhang","year":"2021","journal-title":"Mediators Inflamm"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705291","article-title":"Effects of heparin and related molecules upon neutrophil aggregation and elastase release","volume":"139","author":"Brown","year":"2003","journal-title":"vitro Br J Pharmacol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2019.01.020","article-title":"Unfractionated heparin alleviates sepsis-induced acute lung injury by protecting tight junctions","volume":"238","author":"Liu","year":"2019","journal-title":"J Surg Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.06.007","article-title":"Unfractionated heparin inhibits histone-mediated coagulation activation and thrombosis in mice","volume":"193","author":"Li","year":"2020","journal-title":"Thromb Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/978-3-030-34521-1_20","article-title":"Non-anticoagulant heparins as heparanase inhibitors","volume":"1221","author":"Cassinelli","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-021-01578-w","article-title":"Unfractionated heparin attenuated histone-induced pulmonary syndecan-1 degradation in mice: a preliminary study on the roles of heparinase pathway","volume":"45","author":"Fu","year":"2022","journal-title":"Inflammation"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-514984","article-title":"Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis","volume":"123","author":"Wildhagen","year":"2014","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2021.04.019","article-title":"A focus on the roles of histones in health and diseases","volume":"94","author":"Moiana","year":"2021","journal-title":"Clin Biochem"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12959-018-0190-4","article-title":"Circulating histone H3 levels in septic patients are associated with coagulopathy, multiple organ failure, and death: a single-center observational study","volume":"17","author":"Yokoyama","year":"2019","journal-title":"Thromb J"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.3A0620-342R","article-title":"Histone H4 directly stimulates neutrophil activation through membrane permeabilization","volume":"109","author":"Hsieh","year":"2021","journal-title":"J Leukoc Biol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1146685","article-title":"Heparan sulfates and heparan sulfate binding proteins in sepsis","volume":"10","author":"Liao","year":"2023","journal-title":"Front Mol Biosci"},{"key":"B73","doi-asserted-by":"publisher","first-page":"13706","DOI":"10.3390\/ijms232213706","article-title":"FSAP protects against histone-mediated increase in endothelial permeability","volume":"23","author":"Cui","year":"2022","journal-title":"In Vitro Int J Mol Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/micc.12782","article-title":"Histone-stimulated platelet adhesion to mouse cremaster venules in vivo is dependent on von Willebrand factor","volume":"29","author":"Courson","year":"2022","journal-title":"Microcirculation"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.650184","article-title":"Circulating histones in sepsis: potential outcome predictors and therapeutic targets","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233644","article-title":"Heparin and non-anticoagulant heparin attenuate histone-induced inflammatory responses in whole blood","volume":"15","author":"Hogwood","year":"2020","journal-title":"PloS One"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0000000000002387","article-title":"Unfractionated heparin attenuates histone-mediated cytotoxicity in vitro and prevents intestinal microcirculatory dysfunction in histone-infused rats","volume":"87","author":"Zhu","year":"2019","journal-title":"J Trauma Acute Care Surg"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jointm.2022.02.001","article-title":"HMGB1 is a critical molecule in the pathogenesis of Gram-negative sepsis","volume":"2","author":"Andersson","year":"2022","journal-title":"J Intensive Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3390\/ph16040584","article-title":"Heparin, low molecular weight heparin, and non-anticoagulant derivatives for the treatment of inflammatory lung disease","volume":"16","author":"Shute","year":"2023","journal-title":"Pharm (Basel)"},{"key":"B80","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.immuni.2021.01.007","article-title":"Heparin prevents caspase-11-dependent septic lethality independent of anticoagulant properties","volume":"54","author":"Tang","year":"2021","journal-title":"Immunity"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0000000000001900","article-title":"Heparin binding protein for the early diagnosis and prognosis of sepsis in the emergency department: the prompt multicenter study","volume":"57","author":"Katsaros","year":"2022","journal-title":"Shock"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202200228RRRRR","article-title":"Transforming growth factor-\u03b2 receptor type 2 is required for heparin-binding protein-induced acute lung injury and vascular leakage for transforming growth factor-\u03b2\/Smad\/Rho signaling pathway activation","volume":"36","author":"Liu","year":"2022","journal-title":"FASEB J"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0000000000000862","article-title":"Heparin-binding protein (HBP): A causative marker and potential target for heparin treatment of human sepsis-induced acute kidney injury","volume":"48","author":"Fisher","year":"2017","journal-title":"Shock"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1495260\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:10:59Z","timestamp":1733443859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1495260\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":83,"alternative-id":["10.3389\/fimmu.2024.1495260"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1495260","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]},"article-number":"1495260"}}